---
title: "为什么百时美施贵宝的股票在周四下跌？"
description: "第二季度收入增长至 122.7 亿美元，超出预期；每股收益为 1.46 美元，低于 1.58 美元的市场共识。2025 年每股收益指引下调至 6.35-6.65 美元；销售前景上调至 465 亿-475 亿美元。今天获取三份独家 “十大股票” 强力名单的特别访问权限，名单每日更新"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/251033771.md"
published_at: "2025-07-31T15:07:05.000Z"
---

# 为什么百时美施贵宝的股票在周四下跌？

> 第二季度收入增长至 122.7 亿美元，超出预期；每股收益为 1.46 美元，低于 1.58 美元的市场共识。2025 年每股收益指引下调至 6.35-6.65 美元；销售前景上调至 465 亿-475 亿美元。今天获取三份独家 “十大股票” 强力名单的特别访问权限，名单每日更新

Q2 revenue rose to $12.27 billion, beating estimates; EPS of $1.46 missed the $1.58 consensus. 2025 EPS guidance cut to $6.35-$6.65; sales outlook raised to $46.5 billion-$47.5 billion. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

### Related Stocks

- [BMY.US - 百时美施贵宝](https://longbridge.com/zh-CN/quote/BMY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Key facts: Bristol Myers Squibb's Opdivo gets FDA priority review; Dividend raised to $0.63; Hematology pipeline enhancements underway | Bristol Myers Squibb's Opdivo has received FDA priority review for expanded approval in treating untreated stage III or  | [Link](https://longbridge.com/zh-CN/news/269425451.md) |
| Bayer's stock is jumping on a stroke drug trial - and so is Bristol Myers Squibb | Bayer's stock surged 11% after a successful late-stage trial of its stroke drug, Asundexian, which significantly reduced | [Link](https://longbridge.com/zh-CN/news/267196796.md) |
| Herbalife (HLF) To Report Earnings Tomorrow: Here Is What To Expect | Herbalife will report its earnings results tomorrow, with analysts expecting a revenue growth of 2.5% year-on-year to $1 | [Link](https://longbridge.com/zh-CN/news/276090591.md) |
| Salesforce CEO Marc Benioff's ICE joke was delivered at a difficult time for his company | Salesforce CEO Marc Benioff's ICE joke was delivered at a difficult time for his company | [Link](https://longbridge.com/zh-CN/news/275896154.md) |
| AB Inbev CFO Fernando Tennenbaum: 2026 will hopefully be a more normal year on costs, we see further opportunities to expand margin | AB Inbev CFO Fernando Tennenbaum: 2026 will hopefully be a more normal year on costs, we see further opportunities to ex | [Link](https://longbridge.com/zh-CN/news/275819045.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。